1128-P: SGLT2 Inhibition Increases Serum Copeptin in Adults with Type 1 Diabetes (T1D)
Yuliya Lytvyn(University Health Network), David Z.I. Cherney(University Health Network), Petter Bjornstad(University of Colorado Denver), Alexandra Katz(University of Toronto), Sunita Singh(University Health Network), Linh T. Chung, Bruce A. Perkins(Sinai Health System), Carissa Vinovskis(University of Colorado Denver), Lucas C. Godoy(University of Toronto)
Cited by 0
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life
|JAMA Cardiology|2020|248
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189